Amr et al. [46] explored the promise of two previously reported miRNAs (miR-122 and miR-224) as biomarkers for early stage HCC diagnosis, in comparison to the conventional serum marker, alpha-fetoprotein (AFP), which has a modest accuracy of detecting early stage HCC [47]. This evidence concerns the gene AFP and hepatocellular carcinoma.